Redose
Tirzepatide is an injectable peptide medication that simultaneously activates two hormonal pathways involved in blood sugar regulation and appetite control. It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and it represents the first approved dual GLP-1/GIP agonist. Sometimes referred to as a "twincretin," it demonstrated meaningfully larger reductions in body weight and HbA1c compared to prior GLP-1-only agents in large-scale clinical trials.
What is Tirzepatide
Tirzepatide is a synthetic polypeptide made up of 39 amino acids. It is structurally based on the native GIP hormone, with modifications that also allow it to bind and activate GLP-1 receptors. Eli Lilly developed the compound, which was approved by the FDA in May 2022 under the brand name Mounjaro for adults with type 2 diabetes mellitus (T2DM). In November 2023, a second FDA approval followed under the brand name Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related health condition.
Because it targets both the GLP-1 and GIP receptors, it belongs to a distinct pharmacological class from older GLP-1-only drugs such as semaglutide or liraglutide, though its practical uses overlap substantially. See the full side-by-side at /compare/semaglutide-vs-tirzepatide.
How it Works
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both incretin hormones released from the gut in response to food intake. Together, they signal the pancreas to release insulin in a glucose-dependent manner, meaning insulin output rises when blood glucose is elevated and drops off when levels normalize, which limits the risk of hypoglycemia compared to some older diabetes drugs.
Tirzepatide activates both receptors simultaneously. The GLP-1 component slows gastric emptying, reduces appetite, suppresses glucagon release, and promotes satiety. The GIP component amplifies insulin secretion and appears to improve insulin sensitivity in adipose tissue and skeletal muscle, as well as increasing circulating levels of adiponectin, a hormone that plays a role in fat metabolism. The combination appears to produce greater effects on appetite suppression and weight loss than GLP-1 activation alone.
Pharmacokinetically, tirzepatide has a bioavailability of roughly 80% after subcutaneous injection. It reaches peak serum concentrations within 8 to 72 hours and has a half-life of approximately 5 days, which allows for once-weekly dosing. It is highly bound to plasma albumin (approximately 99%) and is metabolized into individual amino acids through proteolytic cleavage, beta-oxidation, and amide hydrolysis across multiple tissues.
What the Research Says
The SURPASS clinical trial program, a series of large randomized controlled trials, evaluated tirzepatide against placebo, semaglutide, dulaglutide, insulin degludec, and insulin glargine in adults with T2DM. Across these studies, tirzepatide consistently reduced HbA1c by approximately 2.0 to 2.4 percentage points from baseline and produced substantial body weight reductions.
In the SURPASS-5 trial, patients receiving 5 mg per week saw body weight drop by roughly 5.4 kg over 40 weeks, while those on the 15 mg dose saw reductions of approximately 10.5 kg. Among adults without diabetes who were treated specifically for obesity (the SURMOUNT trials), weight reduction over 72 weeks ranged from approximately 16.5% to 22.4% of baseline body weight, depending on dose.
In head-to-head comparisons, tirzepatide outperformed semaglutide on both HbA1c reduction and weight loss endpoints in the SURPASS-2 trial. The American Diabetes Association categorizes tirzepatide as a highly effective option for achieving both glycemic control and weight reduction. Research into additional applications, including non-alcoholic fatty liver disease and sleep apnea, is ongoing, but tirzepatide is not approved for those indications at this time.
Typical Dosing
The following reflects the FDA-approved prescribing schedule. Dosing is individualized in clinical practice. This information is not a substitute for guidance from a licensed healthcare provider.
| Phase | Dose | Duration |
|---|---|---|
| Initiation | 2.5 mg subcutaneously once weekly | 4 weeks |
| Step 1 | 5 mg once weekly | At least 4 weeks |
| Step 2 (optional) | 7.5 mg once weekly | At least 4 weeks |
| Step 3 (optional) | 10 mg once weekly | At least 4 weeks |
| Step 4 (optional) | 12.5 mg once weekly | At least 4 weeks |
| Maximum | 15 mg once weekly | Ongoing as tolerated |
The 2.5 mg starting dose is intended to improve tolerability, not to produce significant glucose or weight effects on its own. Dose escalation is guided by individual response and tolerance of gastrointestinal side effects. If a dose is missed, it can be administered within 4 days (96 hours); otherwise, skip the missed dose and resume the regular weekly schedule.
For guidance on injection technique and site rotation, see /guides/injection-site-rotation. Tirzepatide is injected subcutaneously in the abdomen, thigh, or upper arm.
Side Effects and Safety
Most people tolerate tirzepatide reasonably well, and the overall safety profile is broadly similar to that of GLP-1 receptor agonists. The most common side effects are gastrointestinal and tend to be most prominent during dose escalation:
- Nausea and diarrhea (reported in up to approximately 10% of users in clinical trials)
- Vomiting and constipation (less frequent)
- Reduced appetite (common; contributes to weight loss outcomes)
- Injection-site reactions (mild; comparable to rates seen with GLP-1 agents)
Less common but clinically relevant considerations include:
- Hypoglycemia: Low risk when used without insulin or sulfonylureas; risk rises when combined with those agents.
- Pancreatitis: A theoretical risk consistent with GLP-1 class effects. Patients should seek immediate care for severe abdominal pain.
- Acute kidney injury: Rare; typically secondary to dehydration from gastrointestinal losses. Adequate hydration is important.
- Gallbladder disease: Cases of cholelithiasis and cholecystitis have been reported, possibly linked to rapid weight loss.
- Diabetic retinopathy: Rapid improvement in glycemic control can temporarily worsen existing retinopathy. Monitoring is appropriate in affected patients.
- Oral contraceptive efficacy: Tirzepatide delays gastric emptying, which may reduce absorption of oral medications, including hormonal contraceptives. Non-oral contraception is recommended for at least 4 weeks after initiation and each dose increase.
Boxed warning: Animal studies identified a dose-dependent increase in thyroid C-cell tumor development. Whether this risk applies to humans is not established, but tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN-2. Routine calcitonin monitoring has not been shown to provide early detection in asymptomatic patients and is not universally recommended.
Tirzepatide is not approved for type 1 diabetes, has not been studied in patients with active pancreatitis, and should not be combined with other GLP-1 receptor agonists.
Tracking Tirzepatide with Redose
Tirzepatide follows a structured weekly dosing schedule that involves tracking dose level, injection date, site rotation, and escalation progress over several months. Redose makes this straightforward: log each weekly injection in one tap, let the app rotate your injection sites automatically, and use the dose calculator to keep your vial inventory and remaining doses accurate as you step through the escalation ladder. Download the app at /#download to get started.
This profile is educational information, not medical advice. Talk to a qualified healthcare provider before starting any protocol.